NNC 191228

Drug Profile

NNC 191228

Latest Information Update: 08 Feb 2000

Price : $50

At a glance

  • Originator Novo Nordisk
  • Class Antipsychotics; Benzothiazoles; Benzoxazoles; Carbamates
  • Mechanism of Action Alpha 1 adrenergic receptor antagonists; Dopamine receptor antagonists; Serotonin 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Schizophrenia

Most Recent Events

  • 08 Feb 2000 No-Development-Reported for Schizophrenia in Denmark (Unknown route)
  • 02 May 1997 Preclinical development for Schizophrenia in Denmark (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top